Prostate Cancer News and Research

Latest Prostate Cancer News and Research

What is the optimal prostate-specific antigen cutoff to determine the success of prostate cancer treatment?

After treatment for metastatic prostate cancer, a drop in prostate-specific antigen (PSA) levels in the blood is an indicator that the treatment is working.

13 Aug 2026

Ultra-processed foods linked to higher prostate cancer risk in men

Ultra-processed foods (UPFs) account for nearly 60% of adults' and 70% of children's energy intake in the United States.

12 Aug 2026

Genetic tool turns soft cancer cells into immune targets

Researchers at the USC Viterbi School of Engineering and Keck School of Medicine of USC have engineered a remarkable genetic tool that addresses one of the most persistent obstacles in cancer immunotherapy: the physical softness of tumors.

11 Aug 2026

Traditional prostate cancer features fail to predict hormone therapy benefit

A new study led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center found that while traditional pathological features used to classify aggressive prostate cancer -such as high-grade disease, cancer extending outside the prostate and cancer involving the seminal vesicles- after surgery can help identify patients who are more likely to have worse outcomes, they do not predict who will benefit more from adding hormone therapy to postoperative radiation.

10 Aug 2026

Optimal prostate-specific antigen cutoff linked to improved prostate cancer survival

After treatment for metastatic prostate cancer, a drop in prostate-specific antigen (PSA) levels in the blood is an indicator that the treatment is working.

10 Aug 2026

Early radionuclide therapy delays progression in metastatic prostate cancer

Earlier use of a targeted radionuclide therapy delays metastatic prostate cancer progression when administered as part of a trio of drugs, according to a phase 3 clinical trial led by Weill Cornell Medicine, NewYork-Presbyterian, Memorial Sloan Kettering Cancer Center and investigators at several other institutions worldwide.

6 Aug 2026

Ferroptosis-based therapy shows promise for advanced prostate cancer treatment

A recent review explores the rapidly expanding field of ferroptosis-based therapy for prostate cancer, presenting ferroptosis as a promising strategy to overcome resistance in advanced and castration-resistant prostate cancer (CRPC).

6 Aug 2026

Study identifies a novel direct drug target for head and neck squamous cell carcinoma

Chemotherapy remains a cornerstone of treatment for head and neck cancers, the seventh-most common cancer type worldwide.

6 Aug 2026

Older men’s sexual priorities extend well beyond erectile function

A web-based survey of 6,000 Japanese men aged 50 or older found that sexual arousal was the function they most wanted to preserve, while erection became more highly valued as erectile function worsened. Erection showed the earliest age-related decline pattern, whereas ejaculation was the function most often reported as lost in older age.

6 Aug 2026

AI tool helps customize radiopharmaceutical therapy dosing

Radiopharmaceutical therapy (RPT) has made great strides over the last 50 years, having only recently received FDA approval to treat prostate cancer. But despite the progress-and billions of dollars of industry investments-one area that has lagged behind is dosing, which is still one-size-fits-all.

4 Aug 2026

UCLA researchers find strategy to improve prostate cancer therapies

UCLA researchers have identified a promising strategy to make a new class of targeted cancer therapies more effective against one of the deadliest forms of prostate cancer, potentially overcoming treatment resistance that has limited their success.

3 Aug 2026

DNA enhancer hubs control cancer genes in prostate tumors

Enhancers are pieces of DNA that act like switches, regulating when genes are turned on and off and how strongly they are activated.

22 Jul 2026

New tumor organoids strengthen precision oncology research

Significant advances have been made in the development of patient-derived tumor "organoids" for preclinical research, in two new studies led by Weill Cornell Medicine investigators.

20 Jul 2026

New ctDNA blood test improves personalized prostate cancer treatment

A noninvasive DNA blood test can identify metastatic castration-resistant prostate cancer (mCRPC) patients who are most likely to benefit from 223Ra radiopharmaceutical therapy and monitor their progress throughout treatment, according to new research published in the July issue of The Journal of Nuclear Medicine.

17 Jul 2026

New guideline offers recommendations for testosterone replacement therapy use

The Society's Clinical Practice Guideline on testosterone replacement therapy in men with hypogonadism offers recommendations on appropriate testing and prescribing practices.

16 Jul 2026

Breast and prostate cancer survival worsens with metabolic syndrome

A SEER-Medicare analysis of more than 200,000 adults aged 66 and older found that metabolic syndrome was associated with about twice the adjusted hazard of death from any cause after breast or prostate cancer. The condition was also linked to higher cancer-specific, cardiovascular-specific, and liver-failure-specific mortality, although the observational design prevents causal conclusions.

14 Jul 2026

New generation approaches revive BET protein inhibitors in solid tumors

BET proteins, especially BRD4, drive oncogenic transcription in solid tumours. First‑generation inhibitors (JQ1, molibresib, birabresib) showed preclinical promise but failed clinically due to modest efficacy, dose‑limiting thrombocytopenia, and resistance (isoform switching, compensatory PI3K/AKT/WNT signalling).

11 Jul 2026

New form of hereditary prostate cancer can cause aggressive disease at a young age

Researchers at the University of British Columbia have identified a new form of hereditary prostate cancer that, while rare, can cause aggressive disease at a young age.

9 Jul 2026

Imaging scans detect prostate cancer progression despite stable PSA levels

Patients with advanced prostate cancer may need periodic imaging scans to catch tumor growth even with stable levels of prostate-specific antigen (PSA), a protein in the blood that doctors routinely monitor for cancer progression, according to an analysis led by researchers at Weill Cornell Medicine and Duke University.

1 Jul 2026